Canada · Delayed Price · Currency is CAD Knight Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Record 2025 revenues of CAD 452 million (up 24%) and adjusted EBITDA of CAD 73 million were driven by strong product launches and portfolio expansion. 2026 guidance targets CAD 490–510 million in revenue with continued investment in launches and integration benefits.
Fiscal Year 2024
-
Record revenues and strong portfolio growth were achieved despite currency headwinds and increased operating expenses. Guidance for 2024 is maintained, with new product launches and a robust pipeline expected to drive future growth.
-
Record Q2 revenue and EBITDA growth driven by promoted products and new launches, with raised 2024 guidance reflecting strong pipeline progress and favorable currency trends. Cash position remains robust, and disciplined M&A continues to offset generic pressure.